Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, Pilli D, Patrick E, van der Walt A, Monif M, Tantsis EM, Yiu EM, Vucic S, Henderson APD, Fok A, Fraser CL, Lechner-Scott J, Reddel SW, Broadley S, Barnett MH, Brown DA, Lunemann JD, Dale RC, Brilot F; Australasian and New Zealand MOG Study Group.

Acta Neuropathol Commun. 2019 Sep 3;7(1):145. doi: 10.1186/s40478-019-0786-3.

2.

Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS.

Wang C, Barnett MH, Yiannikas C, Barton J, Parratt J, You Y, Graham SL, Klistorner A.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 16;6(5). pii: e593. doi: 10.1212/NXI.0000000000000593. Print 2019 Sep.

3.

The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis.

Law LY, Riminton DS, Nguyen M, Barnett MH, Reddel SW, Hardy TA.

Neurology. 2019 Aug 27;93(9):390-405. doi: 10.1212/WNL.0000000000008015. Review.

PMID:
31451586
4.

Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis.

Silsby M, Sánchez P, Spies JM, Frith J, Barton J, Beadnall HN, Barnett MH, Reddel SW, Hardy TA.

Mult Scler Relat Disord. 2019 Jul 20;35:104-107. doi: 10.1016/j.msard.2019.07.013. [Epub ahead of print]

PMID:
31362165
5.

Computerized Cognitive Training in Multiple Sclerosis: A Systematic Review and Meta-analysis.

Lampit A, Heine J, Finke C, Barnett MH, Valenzuela M, Wolf A, Leung IHK, Hill NTM.

Neurorehabil Neural Repair. 2019 Sep;33(9):695-706. doi: 10.1177/1545968319860490. Epub 2019 Jul 22.

PMID:
31328637
6.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
7.

The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol.

Sesel AL, Sharpe L, Beadnall HN, Barnett MH, Szabo M, Naismith SL.

BMC Neurol. 2019 Jun 14;19(1):129. doi: 10.1186/s12883-019-1356-9.

8.

The electrophysiological assessment of visual function in Multiple Sclerosis.

Barton JL, Garber JY, Klistorner A, Barnett MH.

Clin Neurophysiol Pract. 2019 May 8;4:90-96. doi: 10.1016/j.cnp.2019.03.002. eCollection 2019. Review.

9.

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.

Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C.

Curr Opin Neurol. 2019 Jun;32(3):305-312. doi: 10.1097/WCO.0000000000000701.

PMID:
30985373
10.

Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

Hartung HP, Graf J, Aktas O, Mares J, Barnett MH.

Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.

PMID:
30985371
11.

Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy.

Garg N, Park SB, Howells J, Vucic S, Yiannikas C, Mathey EK, Nguyen T, Noto Y, Barnett MH, Krishnan AV, Spies J, Bostock H, Pollard JD, Kiernan MC.

Eur J Neurol. 2019 Aug;26(8):1121-1129. doi: 10.1111/ene.13953. Epub 2019 Apr 26.

PMID:
30882969
12.

Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes).

Triplett JD, Buzzard KA, Lubomski M, Riminton DS, Barnett MH, Welgampola MS, Halmagyi GM, Nguyen M, Landau K, Lee AG, Plant GT, Fraser CL, Reddel SW, Hardy TA.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):882-894. doi: 10.1136/jnnp-2018-319002. Epub 2019 Mar 9. Review.

PMID:
30852493
13.

Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

Beadnall HN, Wang C, Van Hecke W, Ribbens A, Billiet T, Barnett MH.

Ther Adv Neurol Disord. 2019 Jan 25;12:1756286418823462. doi: 10.1177/1756286418823462. eCollection 2019.

14.

Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.

You Y, Zhu L, Zhang T, Shen T, Fontes A, Yiannikas C, Parratt J, Barton J, Schulz A, Gupta V, Barnett MH, Fraser CL, Gillies M, Graham SL, Klistorner A.

Ophthalmology. 2019 Jun;126(6):801-810. doi: 10.1016/j.ophtha.2019.01.016. Epub 2019 Feb 1.

15.

Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome.

Nathani D, Barnett MH, Spies J, Pollard J, Wang MX, Kiernan MC.

Muscle Nerve. 2019 Jun;59(6):643-649. doi: 10.1002/mus.26431. Epub 2019 Feb 23.

PMID:
30702153
16.

Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis.

Ebrahimkhani S, Vafaee F, Hallal S, Wei H, Lee MYT, Young PE, Satgunaseelan L, Beadnall H, Barnett MH, Shivalingam B, Suter CM, Buckland ME, Kaufman KL.

NPJ Precis Oncol. 2018 Dec 12;2:28. doi: 10.1038/s41698-018-0071-0. eCollection 2018.

17.

Pathophysiological basis of low contrast visual acuity loss in multiple sclerosis.

Triplett JD, Yiannikas C, Barnett MH, Parratt J, Barton J, Graham SL, You Y, Klistorner A.

Ann Clin Transl Neurol. 2018 Oct 24;5(12):1505-1512. doi: 10.1002/acn3.659. eCollection 2018 Dec.

18.

Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.

Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ, Ma DDF.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):514-521. doi: 10.1136/jnnp-2018-319446. Epub 2018 Dec 11.

PMID:
30538138
19.

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.

Reddel SW, Barnett MH, Riminton S, Dugal T, Buzzard K, Wang CT, Fitzgerald F, Beadnall HN, Erickson D, Gahan D, Wang D, Ackland T, Thompson R.

Mult Scler. 2019 Jul;25(8):1124-1131. doi: 10.1177/1352458518783673. Epub 2018 Jun 18.

PMID:
29911471
20.

Diffusivity in the core of chronic multiple sclerosis lesions.

Klistorner A, Wang C, Yiannikas C, Parratt J, Barton J, You Y, Graham SL, Barnett MH.

PLoS One. 2018 Apr 25;13(4):e0194142. doi: 10.1371/journal.pone.0194142. eCollection 2018.

21.

We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Yes.

Garber JY, Barnett MH.

Mult Scler. 2018 Sep;24(10):1272-1274. doi: 10.1177/1352458518770970. Epub 2018 Apr 16. No abstract available.

PMID:
29656673
22.

The evolution of "No Evidence of Disease Activity" in multiple sclerosis.

Lu G, Beadnall HN, Barton J, Hardy TA, Wang C, Barnett MH.

Mult Scler Relat Disord. 2018 Feb;20:231-238. doi: 10.1016/j.msard.2017.12.016. Epub 2017 Dec 25. Review.

PMID:
29579629
23.

Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study.

Klistorner A, Wang C, Yiannikas C, Parratt J, Dwyer M, Barton J, Graham SL, You Y, Liu S, Barnett MH.

Neuroimage Clin. 2017 Dec 8;17:1028-1035. doi: 10.1016/j.nicl.2017.12.010. eCollection 2018.

24.

White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.

Wang C, Klistorner A, Ly L, Barnett MH.

PLoS One. 2018 Jan 17;13(1):e0191131. doi: 10.1371/journal.pone.0191131. eCollection 2018.

25.

Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS.

You Y, Graham EC, Shen T, Yiannikas C, Parratt J, Gupta V, Barton J, Dwyer M, Barnett MH, Fraser CL, Graham SL, Klistorner A.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e427. doi: 10.1212/NXI.0000000000000427. eCollection 2018 Jan. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jan 31;5(2):e444.

26.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15.

27.

Exosomal microRNA signatures in multiple sclerosis reflect disease status.

Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, Beadnall H, Barnett MH, Suter CM, Buckland ME.

Sci Rep. 2017 Oct 30;7(1):14293. doi: 10.1038/s41598-017-14301-3.

28.

Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions.

Aw ST, Chen L, Todd MJ, Barnett MH, Halmagyi GM.

J Neurol. 2017 Oct;264(10):2119-2129. doi: 10.1007/s00415-017-8607-8. Epub 2017 Sep 6.

PMID:
28879396
29.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

30.

Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.

Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N, Yiannikas C, Lin CS, Spies JM, Ghaoui R, Barnett MH, Vucic S, Pollard JD, Kiernan MC.

J Neuroimmunol. 2017 Aug 15;309:41-46. doi: 10.1016/j.jneuroim.2017.05.002. Epub 2017 May 13.

PMID:
28601286
31.

Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes.

Dale RC, Barnett MH, Kiernan MC.

J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):713-714. doi: 10.1136/jnnp-2017-315724. Epub 2017 Jun 8. No abstract available.

PMID:
28596249
32.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

33.

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

De Stefano N, Silva DG, Barnett MH.

CNS Drugs. 2017 Apr;31(4):289-305. doi: 10.1007/s40263-017-0415-2. Review.

34.

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH.

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8. No abstract available.

PMID:
28179462
35.

Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework.

Jain S, Ribbens A, Sima DM, Cambron M, De Keyser J, Wang C, Barnett MH, Van Huffel S, Maes F, Smeets D.

Front Neurosci. 2016 Dec 19;10:576. doi: 10.3389/fnins.2016.00576. eCollection 2016.

36.

Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.

Beadnall HN, Gill AJ, Riminton S, Barnett MH.

Neurology. 2016 Dec 13;87(24):2595-2597. Epub 2016 Nov 16. No abstract available.

PMID:
27856777
37.

Neurological deficit following stereotactic radiosurgery for trigeminal neuralgia.

Kemp S, Allan RS, Patanjali N, Barnett MH, Jonker BP.

J Clin Neurosci. 2016 Dec;34:229-231. doi: 10.1016/j.jocn.2016.09.029. Epub 2016 Oct 17.

PMID:
27760694
38.

Diffusivity in multiple sclerosis lesions: At the cutting edge?

Klistorner A, Wang C, Fofanova V, Barnett MH, Yiannikas C, Parratt J, You Y, Graham SL.

Neuroimage Clin. 2016 Jul 5;12:219-26. doi: 10.1016/j.nicl.2016.07.003. eCollection 2016.

39.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954
40.

Wallerian Degeneration in the Corticospinal Tract Following Tumefactive Demyelination: Conventional and Advanced Magnetic Resonance Imaging.

Hardy TA, Wang C, Beadnall HN, Lagopoulos J, Barnett Y, Klistorner A, Barnett MH.

Can J Neurol Sci. 2016 Sep;43(5):726-7. doi: 10.1017/cjn.2016.253. Epub 2016 Jul 15. No abstract available.

PMID:
27417915
41.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
42.

Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Graham EC, You Y, Yiannikas C, Garrick R, Parratt J, Barnett MH, Klistorner A.

Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2311-7. doi: 10.1167/iovs.15-19047.

PMID:
27127930
43.

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application.

Wang C, Beadnall HN, Hatton SN, Bader G, Tomic D, Silva DG, Barnett MH.

J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):754-7. doi: 10.1136/jnnp-2015-312304. Epub 2016 Apr 12.

44.

Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of tissue damage.

Barnett MH, Mathey E, Kiernan MC, Pollard JD.

Curr Opin Neurol. 2016 Jun;29(3):213-21. doi: 10.1097/WCO.0000000000000334. Review.

PMID:
27058223
45.

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.

Zinger A, Latham SL, Combes V, Byrne S, Barnett MH, Hawke S, Grau GE.

Mult Scler. 2016 Dec;22(14):1883-1887. Epub 2016 Mar 1.

PMID:
26931477
46.

Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.

Barnett MH, McLeod JG, Hammond SR, Kurtzke JF.

J Neurol. 2016 Apr;263(4):792-8. doi: 10.1007/s00415-016-8059-6. Epub 2016 Feb 25.

PMID:
26914927
47.

Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.

Klistorner A, Wang C, Yiannikas C, Graham SL, Parratt J, Barnett MH.

PLoS One. 2016 Feb 22;11(2):e0149245. doi: 10.1371/journal.pone.0149245. eCollection 2016.

48.

Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barré syndrome.

Garg N, Yuki N, Park SB, Barnett MH, Kiernan MC.

Muscle Nerve. 2016 Jan;53(1):143-6. doi: 10.1002/mus.24935. Epub 2015 Nov 23.

PMID:
26452439
49.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
50.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005

Supplemental Content

Loading ...
Support Center